An observational study in Acute Coronary Syndrome, sponsored by AstraZeneca. Completed at 45 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-05.
Sponsored by AstraZeneca · Observational
The purpose of the study is to analyse patient's acceptance and willingness to participate in a Structured Care Program (SCP) over 12 months following hospital discharge after Acute Coronary Syndrome (ACS) index event.
ProAcor: Prospective Structured Care In Acute Coronary Syndrome Registry
1,461 studies on the registry are indexed under Acute Coronary Syndrome; 267 are open to participants now.
This study's enrollment of 1,006 is above the median of 500 across 561 observational studies indexed under Acute Coronary Syndrome.
Browse Acute Coronary Syndrome studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Regional centres / hospitals with a significant number of ACS patients
Exclusion Criteria:
The number of patients who can be guided through the structured outpatient care program offered within this project by assessing the percentage of patients with diagnosis of Acute Coronary Syndrome (ACS) following the care program.
after collecting all Case Record Form
Time frame: up to 24 months
Description of reasons of premature withdrawal from the program.
after collecting all Case Record Form
Time frame: up to 12 months
Description of changes in quality of life (QoL) during the period of 12 months.
after collecting all Case Record Form
Time frame: up to 12 months
Description of acceptance of the program between subgroups (e.g. gender, risk scores, types of ACS, multimorbidity, medical treatment, therapy).
after collecting all Case Record Form
Time frame: up to 12 months
Description of patients's needs in long term care of ACS.
after collecting all Case Record Form
Time frame: up to 12 months
Description of adherence to guideline conform treatment and patients' compliance with the lifestyle changes recommended by the physician (e.g. body weight, blood pressure, Low Density Lipoprotein (LDL)).
after collecting all Case Record Form
Time frame: up to 12 months
Description of newly occurred cardiac symptoms (e.g. troponin, LVH), as determined by routine examinations by the cardiologists, which cause a declining state of health.
after collecting all Case Record Form
Time frame: up to 12 months
Frequency of changes in ambulant treatment according to the acceptance of the program.
after collecting all Case Record Form
Time frame: up to 12 months
Frequency of newly occurred symptomatic acute cardiac events according to the acceptance of the program.
after collecting all Case Record Form
Time frame: up to 12 months
Frequency of resource use according to the acceptance of the program.
after collecting all Case Record Form
Time frame: up to 12 months
This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca